Published in PLoS One on August 19, 2010
Malaria parasite CelTOS targets the inner leaflet of cell membranes for pore-dependent disruption. Elife (2016) 1.76
Optimising Controlled Human Malaria Infection Studies Using Cryopreserved P. falciparum Parasites Administered by Needle and Syringe. PLoS One (2013) 1.33
Vaccines for malaria: how close are we? Annu Rev Med (2011) 1.20
Pre-erythrocytic malaria vaccines: identifying the targets. Expert Rev Vaccines (2012) 1.07
Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines. Clin Vaccine Immunol (2012) 1.00
Inducing humoral and cellular responses to multiple sporozoite and liver-stage malaria antigens using exogenous plasmid DNA. Infect Immun (2013) 0.94
Identification of non-CSP antigens bearing CD8 epitopes in mice immunized with irradiated sporozoites. Vaccine (2011) 0.92
Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates. Sci Rep (2015) 0.92
Anti-sporozoite antibodies as alternative markers for malaria transmission intensity estimation. Malar J (2014) 0.92
Computational and experimental validation of B and T-cell epitopes of the in vivo immune response to a novel malarial antigen. PLoS One (2013) 0.91
Recent advances in recombinant protein-based malaria vaccines. Vaccine (2015) 0.91
Acquisition and Longevity of Antibodies to Plasmodium vivax Preerythrocytic Antigens in Western Thailand. Clin Vaccine Immunol (2015) 0.87
Analysis of a Multi-component Multi-stage Malaria Vaccine Candidate--Tackling the Cocktail Challenge. PLoS One (2015) 0.86
Discovery of Novel Plasmodium falciparum Pre-Erythrocytic Antigens for Vaccine Development. PLoS One (2015) 0.82
A nonintegrative lentiviral vector-based vaccine provides long-term sterile protection against malaria. PLoS One (2012) 0.81
The case for a rational genome-based vaccine against malaria. Front Microbiol (2015) 0.81
Malaria vaccine clinical trials: what's on the horizon. Curr Opin Immunol (2015) 0.80
Self-adjuvanting bacterial vectors expressing pre-erythrocytic antigens induce sterile protection against malaria. Front Immunol (2013) 0.80
Measuring naturally acquired ex vivo IFN-γ responses to Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites (CelTOS) in Ghanaian adults. Malar J (2015) 0.80
Contrasting Patterns of Serologic and Functional Antibody Dynamics to Plasmodium falciparum Antigens in a Kenyan Birth Cohort. Clin Vaccine Immunol (2015) 0.80
Large screen approaches to identify novel malaria vaccine candidates. Vaccine (2015) 0.80
Progress with viral vectored malaria vaccines: A multi-stage approach involving "unnatural immunity". Vaccine (2015) 0.79
The P. falciparum Cell-Traversal Protein for Ookinetes and Sporozoites as a Candidate for Pre-Erythrocytic and Transmission-Blocking Vaccines. Infect Immun (2016) 0.78
Immunological Cross-Reactivity between Malaria Vaccine Target Antigen P48/45 in Plasmodium vivax and P. falciparum and Cross-Boosting of Immune Responses. PLoS One (2016) 0.77
Seroprevalence of Antibodies against Plasmodium falciparum Sporozoite Antigens as Predictive Disease Transmission Markers in an Area of Ghana with Seasonal Malaria Transmission. PLoS One (2016) 0.75
Antibodies elicited during natural infection in a predominantly Plasmodium falciparum transmission area cross-react with sexual stage-specific antigen in P. vivax. Acta Trop (2017) 0.75
Studies on Immunogenicity and Antigenicity of Baculovirus-Expressed Binding Region of Plasmodium falciparum EBA-140 Merozoite Ligand. Arch Immunol Ther Exp (Warsz) (2015) 0.75
Design, structure prediction and molecular dynamics simulation of a fusion construct containing malaria pre-erythrocytic vaccine candidate, PfCelTOS, and human interleukin 2 as adjuvant. BMC Bioinformatics (2016) 0.75
Complex Minigene Library Vaccination for Discovery of Pre-Erythrocytic Plasmodium T Cell Antigens. PLoS One (2016) 0.75
Assessment of the Plasmodium falciparum pre-erythrocytic antigen UIS3 as a potential candidate for a malaria vaccine. Infect Immun (2016) 0.75
Plasmodium vivax Cell Traversal Protein for Ookinetes and Sporozoites (PvCelTOS) gene sequence and potential epitopes are highly conserved among isolates from different regions of Brazilian Amazon. PLoS Negl Trop Dis (2017) 0.75
Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites: Naturally Acquired Humoral Immune Response and B-Cell Epitope Mapping in Brazilian Amazon Inhabitants. Front Immunol (2017) 0.75
What Is Known about the Immune Response Induced by Plasmodium vivax Malaria Vaccine Candidates? Front Immunol (2017) 0.75
Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine. Clin Vaccine Immunol (2017) 0.75
Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet (2004) 9.24
An inverse relationship between T cell receptor affinity and antigen dose during CD4(+) T cell responses in vivo and in vitro. Proc Natl Acad Sci U S A (1999) 3.15
Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data. Proc Natl Acad Sci U S A (2003) 2.38
Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children. J Infect Dis (2009) 2.36
Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'. Parasite Immunol (2009) 2.17
Heterologous protein expression is enhanced by harmonizing the codon usage frequencies of the target gene with those of the expression host. PLoS One (2008) 2.07
Antibody-induced ultrastructural changes of malarial sporozoites. J Immunol (1976) 1.97
Specificity of protective immunity produced by x-irradiated Plasmodium berghei sporozoites. Nature (1969) 1.89
CelTOS, a novel malarial protein that mediates transmission to mosquito and vertebrate hosts. Mol Microbiol (2006) 1.84
Differential transcriptome profiling identifies Plasmodium genes encoding pre-erythrocytic stage-specific proteins. Mol Microbiol (2004) 1.76
Simple centrifugation method for rapid separation of sporozoites from mosquitoes. J Parasitol (1984) 1.62
Malaria sporozoites leave behind trails of circumsporozoite protein during gliding motility. J Protozool (1988) 1.58
Studies on the control of antibody synthesis. VI. Effect of antigen dose and time after immunization on antibody affinity and heterogeneity in the mouse. Clin Exp Immunol (1974) 1.22
Immune responses induced by intramuscular or gene gun injection of protective deoxyribonucleic acid vaccines that express the circumsporozoite protein from Plasmodium berghei malaria parasites. J Immunol (1997) 1.17
Genetic vaccination against malaria infection by intradermal and epidermal injections of a plasmid containing the gene encoding the Plasmodium berghei circumsporozoite protein. Infect Immun (2000) 1.00
C3d binding to the circumsporozoite protein carboxy-terminus deviates immunity against malaria. Int Immunol (2005) 0.98
Malaria vaccine: a current perspective. J Vector Borne Dis (2008) 0.93
Removal of the circumsporozoite protein (CSP) glycosylphosphatidylinositol signal sequence from a CSP DNA vaccine enhances induction of CSP-specific Th2 type immune responses and improvesprotection against malaria infection. Eur J Immunol (2001) 0.93
Plasmodium falciparum sporozoite immunization protects against Plasmodium berghei sporozoite infection. Exp Parasitol (1993) 0.92
Comparison of Plasmodium berghei challenge models for the evaluation of pre-erythrocytic malaria vaccines and their effect on perceived vaccine efficacy. Malar J (2010) 0.92
Improved technique for the preparation of water-in-oil emulsions containing protein antigens. Biotechniques (1996) 0.87
Discovery of gene function by expression profiling of the malaria parasite life cycle. Science (2003) 10.57
Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS One (2009) 2.79
Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS One (2009) 2.49
Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine (2005) 2.18
Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial. PLoS One (2008) 1.90
Surveillance for malaria elimination in Swaziland: a national cross-sectional study using pooled PCR and serology. PLoS One (2012) 1.81
Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design. Proc Natl Acad Sci U S A (2009) 1.72
Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine. Vaccine (2005) 1.68
Enzyme-linked immunosorbent assay for detection of Plasmodium falciparum histidine-rich protein 2 in blood, plasma, and serum. Clin Vaccine Immunol (2008) 1.52
A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli. PLoS One (2009) 1.51
DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS One (2013) 1.47
Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses. PLoS One (2008) 1.47
Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trial. PLoS Clin Trials (2006) 1.47
Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adults. PLoS One (2008) 1.46
The metabolism of primaquine to its active metabolite is dependent on CYP 2D6. Malar J (2013) 1.41
Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan children. PLoS Clin Trials (2006) 1.36
Critical evaluation of different methods for measuring the functional activity of antibodies against malaria blood stage antigens. Am J Trop Med Hyg (2006) 1.30
Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children. J Infect Dis (2011) 1.28
Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum. Vaccine (2004) 1.24
Old world leishmaniasis: an emerging infection among deployed US military and civilian workers. Clin Infect Dis (2004) 1.24
Transcutaneous immunization using colonization factor and heat-labile enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coli. Infect Immun (2002) 1.20
First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers. Vaccine (2013) 1.16
Process development and analysis of liver-stage antigen 1, a preerythrocyte-stage protein-based vaccine for Plasmodium falciparum. Infect Immun (2005) 1.10
Viral vectors for malaria vaccine development. Vaccine (2006) 1.10
Marked variation in MSP-119 antibody responses to malaria in western Kenyan highlands. BMC Infect Dis (2012) 1.07
Cellular and humoral immune effector mechanisms required for sterile protection against sporozoite challenge induced with the novel malaria vaccine candidate CelTOS. Vaccine (2011) 1.03
Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines. Clin Vaccine Immunol (2012) 1.00
Miniaturization of a high-throughput pLDH-based Plasmodium falciparum growth inhibition assay for small volume samples from preclinical and clinical vaccine trials. Am J Trop Med Hyg (2008) 0.99
Suramin and suramin analogues inhibit merozoite surface protein-1 secondary processing and erythrocyte invasion by the malaria parasite Plasmodium falciparum. J Biol Chem (2003) 0.99
Transgenic parasites stably expressing full-length Plasmodium falciparum circumsporozoite protein as a model for vaccine down-selection in mice using sterile protection as an endpoint. Clin Vaccine Immunol (2013) 0.98
C3d binding to the circumsporozoite protein carboxy-terminus deviates immunity against malaria. Int Immunol (2005) 0.98
HIV nonnucleoside reverse transcriptase inhibitors and trimethoprim-sulfamethoxazole inhibit plasmodium liver stages. J Infect Dis (2012) 0.96
Potent malaria transmission-blocking antibody responses elicited by Plasmodium falciparum Pfs25 expressed in Escherichia coli after successful protein refolding. Infect Immun (2014) 0.96
Activation of innate immunity in healthy Macaca mulatta macaques by a single subcutaneous dose of GMP CpG 7909: safety data and interferon-inducible protein-10 kinetics for humans and macaques. Clin Vaccine Immunol (2007) 0.96
Characterization of a human reference standard for antibody to Plasmodium falciparum merozoite surface protein 1(42). Am J Trop Med Hyg (2005) 0.95
Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA. Hum Vaccin Immunother (2012) 0.95
Disruption of the Plasmodium falciparum liver-stage antigen-1 locus causes a differentiation defect in late liver-stage parasites. Cell Microbiol (2011) 0.94
Development of a chimeric Plasmodium berghei strain expressing the repeat region of the P. vivax circumsporozoite protein for in vivo evaluation of vaccine efficacy. Infect Immun (2013) 0.93
Quantification of sporozoite invasion, migration, and development by microscopy and flow cytometry. Methods Mol Biol (2013) 0.92
MSP-1p42-specific antibodies affect growth and development of intra-erythrocytic parasites of Plasmodium falciparum. Malar J (2009) 0.92
Comparison of Plasmodium berghei challenge models for the evaluation of pre-erythrocytic malaria vaccines and their effect on perceived vaccine efficacy. Malar J (2010) 0.92
Anti-sporozoite antibodies as alternative markers for malaria transmission intensity estimation. Malar J (2014) 0.92
Computational and experimental validation of B and T-cell epitopes of the in vivo immune response to a novel malarial antigen. PLoS One (2013) 0.91
Evaluation of immunoglobulin purification methods and their impact on quality and yield of antigen-specific antibodies. Malar J (2008) 0.90
Adjustment of codon usage frequencies by codon harmonization improves protein expression and folding. Methods Mol Biol (2011) 0.89
The effect of antiretrovirals on Plasmodium falciparum liver stages. AIDS (2013) 0.88
Cytokine and antibody responses to Plasmodium falciparum in naïve individuals during a first malaria episode: effect of age and malaria exposure. PLoS One (2013) 0.88
Histidine affinity tags affect MSP1(42) structural stability and immunodominance in mice. Biotechnol J (2011) 0.86
Transfusion-associated babesiosis with an atypical time course after nonmyeloablative transplantation for sickle cell disease. Ann Intern Med (2008) 0.85
Impact of the RTS,S malaria vaccine candidate on naturally acquired antibody responses to multiple asexual blood stage antigens. PLoS One (2011) 0.85
High antibody responses against Plasmodium falciparum in immigrants after extended periods of interrupted exposure to malaria. PLoS One (2013) 0.84
Molecular vaccines for malaria. Hum Vaccin (2010) 0.84
C3d-defined complement receptor-binding peptide p28 conjugated to circumsporozoite protein provides protection against Plasmodium berghei. Vaccine (2007) 0.83
Development, characterization and immunogenicity of a multi-stage, multi-valent Plasmodium falciparum vaccine antigen (FALVAC-1A) expressed in Escherichia coli. Hum Vaccin (2006) 0.83
A chimeric Plasmodium falciparum merozoite surface protein vaccine induces high titers of parasite growth inhibitory antibodies. Infect Immun (2013) 0.82
Molecular adjuvants for malaria DNA vaccines based on the modulation of host-cell apoptosis. Vaccine (2009) 0.82
Evaluation of the immunogenicity and vaccine potential of recombinant Plasmodium falciparum merozoite surface protein 8. Infect Immun (2012) 0.81
Impact of pre-existing MSP1(42)-allele specific immunity on potency of an erythrocytic Plasmodium falciparum vaccine. Malar J (2012) 0.81
Self-adjuvanting bacterial vectors expressing pre-erythrocytic antigens induce sterile protection against malaria. Front Immunol (2013) 0.80
Cardiac infection and sepsis in 3 intravenous bath salts drug users. Clin Infect Dis (2013) 0.78
Pharmacokinetic evaluation of intravenous artesunate in adults with uncomplicated falciparum malaria in Kenya: a phase II study. Malar J (2014) 0.75